All In Biotech

Drug Trial Radar · NCT06650852

A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

A Phase 2 Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and Pegylated Interferon Alpha (PEG-IFNα) in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Oct 31, 2024

Primary completion

Sep 2028

Study completion Sep 2029

Sponsor

Lead sponsor
Brii Biosciences LimitedIndustry
Sponsor type
Industry
First posted
Oct 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2, randomized, double-blind study will evaluate the clinical efficacy and safety of the combination therapy of BRII-179, BRII-835, plus PEG-IFNα compared to PEG-IFNα in adult participants with chronic HBV infection without cirrhosis receiving neucloes(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.

Conditions

  • Chronic Hepatitis B Virus (HBV) Infection

Interventions

  • BRII-179Biological

    BRII-179 will be given via intramuscular injection

  • BRII-835 (VIR-2218)Drug

    BRII-835 will be given via subcutaneous injection

  • PEG-IFNαBiological

    PEG-IFNα will be given via subcutaneous injection

  • Placebo of BRII-179Drug

    Placebo of BRII-179 will be given via intramuscular injection

  • Placebo of BRII-835Drug

    Placebo of BRII-835 will be given via subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage of participants achieving HBsAg seroclearance.Time frame: Up to 48 weeks
  2. Percentage of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).Time frame: Up to 96 weeks

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Investigative Site 86001

    Beijing, Beijing Municipality, China · Recruiting

  • Investigative Site 86003

    Beijing, Beijing Municipality, China · Recruiting

  • Investigative Site 86004

    Beijing, Beijing Municipality, China · Recruiting

  • Investigative Site 86005

    Beijing, Beijing Municipality, China · Recruiting

  • Investigative Site 86016

    Beijing, Beijing Municipality, China · Recruiting

  • Investigative Site 86002

    Guangzhou, Guangdong, China · Recruiting

  • Investigative Site 86013

    Guangzhou, Guangdong, China · Recruiting

  • Investigative Site 86015

    Shenzhen, Guangdong, China · Recruiting

  • Investigative Site 86006

    Shanghai, Shanghai Municipality, China · Recruiting

  • Investigative Site 86007

    Shanghai, Shanghai Municipality, China · Recruiting

  • Investigative Site 86010

    Chengdu, Sichuan, China · Recruiting

  • Investigative Site 86011

    Chengdu, Sichuan, China · Recruiting

  • Investigative Site 86012

    Chengdu, Sichuan, China · Recruiting

  • Investigative Site 86009

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.